Rett Syndrome Phase 2 (RS-001) Which was Really Phase 1 Which Turned Almost into Phase 3 $AVXL

To start talking about the 15 person dosed cohort in RS-001 Phase 2 one has to get on the subject of the dose right away. At 5mg/daily, it seems that $AVXL thought it was dispencing poison to the girls, when the maximum dose is 50mg/daily. By all accounts, that is only 1/10 of the maximum … Continue reading Rett Syndrome Phase 2 (RS-001) Which was Really Phase 1 Which Turned Almost into Phase 3 $AVXL

Aduhelm (Aducanumab) Value vs. Its Truly Restricted Market, and The Same for Blarcamesine $BIIB $AVXL

Biogen surge of $15bln in market capitalization due to Aduhelm approval does match the restricted market the drug faces. I am taking off where Lane Simonian left without giving any numbers in its latest SeekingAlpha article, link: https://seekingalpha.com/article/4435705-post-biogen-post-amyloid-world-for-alzheimers-disease . Following Bazilian study looked at the incidence of all allels of the APOE gene in Late-Onset … Continue reading Aduhelm (Aducanumab) Value vs. Its Truly Restricted Market, and The Same for Blarcamesine $BIIB $AVXL

Post On “Multi-Targeted Ligands (MTDLs) Binding the SIGMAR1 Receptor as Promising Therapeutics” $AVXL Blarcamesine Anavex3-71

The paper of the same title, link here https://www.mdpi.com/1422-0067/22/12/6359 , described number of compounds and their chemistry, among them it mentioned ANAVEX 2-73 and 3-71 as examples of the most studied drugs in the class of MTDLs drugs. It also listed number of other drugs and their targets besides SIGMAR1, touching here on the logic … Continue reading Post On “Multi-Targeted Ligands (MTDLs) Binding the SIGMAR1 Receptor as Promising Therapeutics” $AVXL Blarcamesine Anavex3-71

Two Measures of Efficacy in Alzheimer’s Trials. Blarcamesine $AVXL $SAVA $ANVS

There are two measures by which go trials of Alzheimer's/dementia. The most popular and the most expeditious is the average increase/decrease in MMSE or ADAS-Cog points of the dosed cohort vs. the placebo. The other is taking much more time and is probably more telling of the drugs potential. It is the number of dropouts … Continue reading Two Measures of Efficacy in Alzheimer’s Trials. Blarcamesine $AVXL $SAVA $ANVS

Is There More than Just Alzheimer’s, Parkinson’s and Rett Syndrome in Blarcamesine Bag of Tricks? $AVXL

See press release from Anavex Life Sciences. https://www.anavex.com/anavex-life-sciences-announces-notice-of-allowance-for-u-s-patent-application-anavex2-73-blarcamesine-for-the-treatment-of-cardiac-dysfunctions/ Heart has its own little nervous system which in part is independent from the brain. Blarcamsine as SIGMAR1 agonist does its work as far as we know primarily in the nervous cells. Yet, the SIGMAR1 receptors are expressed in different organs too. I was trying to provide … Continue reading Is There More than Just Alzheimer’s, Parkinson’s and Rett Syndrome in Blarcamesine Bag of Tricks? $AVXL

Implications of Soon to Be Resealed 5 year Data on Extension of Blarcamesine Phase2a for Alzheimer’s in One Chart. $AVXL

See this post first.... https://piotrpeterblog.com/2021/05/18/morbidity-and-disability-in-phase-2a-alzheimers-study-of-blarcamsine-vs-background-morbidity-in-similar-age-control-group-avxl/ Now to the Chart. I will be on a 12 days vacations so might not post anything so I need a more beer money .... Make a one-time donationYour contribution is appreciated.DonateMake a monthly donationYour contribution is appreciated.Donate monthlyMake a yearly donationYour contribution is appreciated.Donate yearly

Who is Following Whose Success? $SAVA $ANVS $AVXL

$SAVA Success Wave Lifting All Boats The released $SAVA data brought about a wave of investment and renewed vigour to investing into smaller Alzheimer's narratives. When most of the news is just shadowing the declines and any number above the initail score is reason for hope. A couple of things are transpiring among the companies … Continue reading Who is Following Whose Success? $SAVA $ANVS $AVXL

The Alzheimer’s Etiology Wars! $AVXL $ANVS

A Battle in Etiology Wars! The most prevalent hypothesis of the etiologies of Alzheimer's disease is the A-Beta Amyloid deposits theory.  The theory has been evolving into few branches.  One of them states that there is production of A-beta in the axions of neurons in response to stress and the toxicity of A-beta works its … Continue reading The Alzheimer’s Etiology Wars! $AVXL $ANVS

Morbidity and Disability in Phase 2a Alzheimer’s Study of Blarcamsine vs. Background Morbidity in Similar Age Control Group $AVXL

I would like to add some additional information to the previously presented analysis on the dropout rate after 5 years. Though the number of remaing subjects in the Phase2a OLE and Humanitarian Extension is rather imprecise as Dr. Missling put it between 21 and 10, I used as reference paper titled Variability in Annual Mini-Mental … Continue reading Morbidity and Disability in Phase 2a Alzheimer’s Study of Blarcamsine vs. Background Morbidity in Similar Age Control Group $AVXL

Anavex Life Sciences Alzheimer’s Phase2a Dropout in Light of Info from Conference Call Q1 2021 Blarcamesine $AVXL

On the 13th of May 2021, Dr Missling had conference call on the Q1 2021 results. The call was very brief but the questions from analysts were more detailed and aimed at elucidating future prospects of the company. One was of interest to me over immediate promises. Namely, question about dropout rate in Phase2a Alzheimer's … Continue reading Anavex Life Sciences Alzheimer’s Phase2a Dropout in Light of Info from Conference Call Q1 2021 Blarcamesine $AVXL